secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001104659-24-080355
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead CMO Merdad Parsey to depart early 2025; successor search begins
----------------------------------------------------------------------

- Chief Medical Officer Merdad Parsey, M.D., Ph.D., will leave Gilead early next year.
- Parsey will remain CMO until Q1 2025 to assist with transition while successor is identified.
- He joined Gilead in November 2019 and oversaw expansion of pipeline to 54 ongoing clinical trials.
- CEO Daniel O'Day praised Parsey's role in doubling the portfolio and advancing virology, oncology, and inflammation.
- No formal departure date; transition expected through Q1 2025 or as mutually agreed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465924080355/0001104659-24-080355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465924080355/tm2419649d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-080355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer